Alternative Liquidity Index SC TO-T/AThird party tender offer statement (amended)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________

Amendment No. 2

to

SCHEDULE TO

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

____________________________

       Sinovac Biotech Ltd. 

---------------------------------------------------------------------------------------------------------------------------------

(Name of Subject Company (Issuer))

Alternative Liquidity Index LP

------------------------------------------------------------------------------------------------------------

(Names of Filing Person (Purchaser))

Common Stock, $0.01 par value

---------------------------------------------------------------------------------------------------------------------------------

(Title of Class of Securities)

P8696W104

---------------------------------------------------------------------------------------------------------------------------------

(CUSIP Number of Class of Securities)

---------------------------------------------------------------------------------------------------------------------------------

Jacob Mohs

Alternative Liquidity Index LP

C/O Alternative Liquidity Capital

11500 Wayzata Blvd. #1050

Minnetonka, MN 55305

(888) 884-8796

info@alternativeliquidity.net

---------------------------------------------------------------------------------------------------------------------------------

(Name, Address and Telephone Number of a Person

Authorized to Receive Notices and Communications on Behalf of Filing Persons)

Calculation of Filing Fee

* This amount represents the maximum amount of the offer.

þ Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

o  Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

þ  third-party tender offer subject to Rule 14d-1

o  issuer tender offer subject to Rule 13e-4

o  going-private transaction subject to Rule 13e-3

o  amendment to Schedule 13D under Rule 13d-2

Check the following box if the filing is a final amendment reporting the results of the tender offer:  þ

FINAL AMENDMENT TO TENDER OFFER

        This Final Amendment to the Tender Offer Statement on Schedule TO (the “Schedule TO”) relates to the offer by Alternative Liquidity Index LP (the “Purchaser”), to purchase for cash, subject to the terms and conditions set forth in the Offer to Purchase, up to a maximum of 10,000,000 shares of Sinovac Biotech Ltd. (the “Company”) at a purchase price of $0.03 per share, net cash to the seller, less any applicable withholding taxes and without interest (the “Purchase Price”), and the related Assignment Form.

The Offer expired on March 12, 2024.   The Offer resulted in the tender by shareholders and acceptance for payment by the Purchaser of a total of 1,325,314 shares.  Following the purchase of all the tendered Shares, the Purchaser will own an aggregate of approximately 1,418,821 shares.  

Item 12.MATERIAL TO BE FILED AS EXHIBITS. 

(a)(1)Offer to Purchase* 

(a)(2)Assignment Form* 

(a)(3)      Letter to Shareholders*

(a)(3)Announcement of Offer* 

*Previously filed on February 2, 2024

Item 12.            INFORMATION REQUIRED BY SCHEDULE 13E-3 

Not applicable
 

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.